At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 240 enrolled
Drug / intervention
Vixarelimab +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2a/b, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of KPL-716 in Reducing Pruritus in Subjects With Prurigo Nodularis
In Brief
A Phase 2 clinical trial evaluating Vixarelimab and Placebo for Prurigo Nodularis and Pruritis. Completed, enrolled 240 participants across 86 sites in 13 countries.
Detailed Summary
Study of the efficacy, safety, tolerability, pharmacokinetics (PK), and immunogenicity of Vixarelimab (KPL-716) in subjects with prurigo nodularis (PN).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPrurigo Nodularis, Pruritis
CountriesAustralia, Austria, Belgium, Canada, Czechia, France, Germany, Italy, Poland, South Korea, Taiwan, United Kingdom, United States
CollaboratorsKiniksa Pharmaceuticals, Ltd.
Timeline
Phase 2CompletedFinished
20192020202120222023202420252026
First PostedJan 2019
Enrollment StartMar 2019
Primary CompletionDec 2022
Study CompletionAug 2023
TodayJul 2026
First PostedJan 25, 2019
Enrollment StartMar 11, 2019
Primary CompletionDec 28, 2022
Study CompletionAug 24, 2023
TodayJul 2, 2026
Enrollment to primary: 3.8 yearsPosted 7.4 years ago
Interventions
Vixarelimabdrug
solution for injection
Placebodrug
solution for injection